Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab + Atezolizumab in ctDNA-positive Stage II Melanoma
NCT05060003Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in melanoma, sponsored by Washington University School of Medicine. Started Nov 2022; status: terminated.
02
Drugs
tiragolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05060003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060003.